A BRD9 degrader 83 was designed and synthesized by Bradner et al. that could induce the degradation of the target protein at nanomolar concentration and also exhibited more pronounced antiproliferative effects in the human AML MOLM-13 cell line than the inhibitor (BRD 9 inhibitor) used for the construction of the PROTAC assemblage (Fig. 10) [322]. The gene discussed is BRD9; the disease is acute myeloid leukemia.